0
Welcome User
Login/Sign Up
Login/Sign Up
₹19990
(Inclusive of all Taxes)
Get Free delivery (₹99) with
Ranizurel 2.3 Injection 0.23 ml belongs to the group of medicines called anti-neovascularisation agents used to treat eye diseases causing vision impairment, such as neovascular (wet) age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, proliferative diabetic retinopathy, and choroidal neovascularization. It is also used to treat retinopathy of prematurity in babies born prematurely.
Ranizurel 2.3 Injection 0.23 ml contains Ranibizumab, a vascular endothelial growth factor A (VEGF-A) antagonist. It binds to VEGF-A (a protein that causes abnormal blood vessel growth and swelling, leading to vision impairment) present in the eyes, blocks its action, and prevents abnormal growth and swelling. It helps stabilise and improve vision.
In some cases, Ranizurel 2.3 Injection 0.23 ml may cause side effects such as eye pain, inflammation, retinal bleeding, dry eye, eye irritation, and redness or itching of the eye. Most of these side effects may not require medical attention and resolve over time. However, you are advised to talk to the doctor if any of the side effects persist or worsen.
Let the doctor know if you are allergic to any components in Ranizurel 2.3 Injection 0.23 ml. Consult the doctor if you are pregnant, think you may be pregnant or planning for pregnancy. Ranizurel 2.3 Injection 0.23 ml is not recommended during breastfeeding. Keep your doctor informed about your health condition and medications to rule out any side effects/interactions.
Ranizurel 2.3 Injection 0.23 ml is used in the treatment of Neovascular (wet) age-related macular degeneration (AMD), macular oedema following retinal vein occlusion (RVO), diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), and choroidal neovascularization (CNV). Also used in premature babies to treat retinopathy of prematurity (ROP). The detailed uses of Ranizurel 2.3 Injection 0.23 ml are as follows:
Ranizurel 2.3 Injection 0.23 ml belongs to the group of medicines called anti-neovascularisation agents used to treat eye diseases causing vision impairment, such as neovascular (wet) age-related macular degeneration (AMD), macular oedema following retinal vein occlusion (RVO), diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), and choroidal neovascularization (CNV). Ranizurel 2.3 Injection 0.23 ml contains Ranibizumab, a vascular endothelial growth factor A (VEGF-A) antagonist, which binds to VEGF-A (a protein which causes abnormal blood vessel growth and swelling, leading to vision impairment) present in the eyes, blocks its action and prevents abnormal growth and swelling. It helps stabilise and improve your vision. This medicine may also be indicated in preterm infants for the treatment of retinopathy of prematurity (ROP).
Consult your doctor
It is not known if alcohol interacts with Ranizurel 2.3 Injection 0.23 ml. Please consult the doctor.
Caution
Ranizurel 2.3 Injection 0.23 ml should not be used during pregnancy unless the benefits outweigh the risks. Consult the doctor if you are pregnant, think you may be pregnant or planning for pregnancy.
Unsafe
It is not known whether Ranizurel 2.3 Injection 0.23 ml passes into breast milk. However, if you are breastfeeding, inform your doctor before receiving Ranizurel 2.3 Injection 0.23 ml.
Caution
Ranizurel 2.3 Injection 0.23 ml may cause temporary vision blurring. Avoid driving or operating heavy machinery if you experience this.
Caution
If you have a history of liver problems, inform the doctor before receiving Ranizurel 2.3 Injection 0.23 ml.
Caution
Dose adjustment may not be needed in patients with renal impairment. However, if you have a history of kidney problems, inform the doctor before receiving Ranizurel 2.3 Injection 0.23 ml.
Caution
Ranizurel 2.3 Injection 0.23 ml is not recommended for children as the safety and effectiveness have not been established except for retinopathy of prematurity (ROP) in babies born prematurely. However, the safety profile in preterm infants has not been established beyond 2 years.
Caution
Ranizurel 2.3 Injection 0.23 ml can generally receive even if you have heart problems, but with careful medical oversight. Studies show that Ranizurel 2.3 Injection 0.23 ml does not significantly increase the risk of heart attack, stroke, or death in patients with cardiovascular conditions. However, if you're at high risk or receiving frequent injections, your doctor may evaluate your heart health more closely before proceeding.
Consult your doctor
Ranizurel 2.3 Injection 0.23 ml is generally not recommended for geriatric patients with certain health risks unless clearly indicated. Due to age-related vulnerabilities, doctors may consider alternative treatments and avoid its use unless the benefits outweigh potential complications.
Have a query?
Do not receive Ranizurel 2.3 Injection 0.23 ml if you are allergic to any of its components, if you have an infection in or around the eye, severe intraocular inflammation (pain or redness in the eye) or if you are breastfeeding. Consult the doctor if you are pregnant, think you may be pregnant or planning for pregnancy. Seek immediate medical attention if you experience worsening eye redness, eye pain or increased discomfort, an increased number of small particles in your vision, blurred or decreased vision, or increased sensitivity to light. Inform the doctor if you have a history of eye conditions, eye treatments, or stroke. Let the doctor know if you are taking any other medicines, including supplements or herbal products.
Drug-Drug Interactions: Inform the doctor if you are using, have recently used or might use any other medicines.
Drug-Food Interactions: No interactions found.
Drug-Disease Interactions: Inform the doctor if you have/had an eye infection, eye inflammation, or stroke.
Login/Sign Up
Login/Sign Up
Lupin Ltd
₹21780
(₹21780.0 per unit)
Disclaimer
